Showing 742 results
-
Ad hoc release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de…
-
Press release /Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84…
-
Press release /EC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
-
Press release /Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
-
Press release /Chiffre d'affaires net de l'exercice 2016 (0% tcc[2]) comparable à celui de l'exercice précédent, grâce à l'excellente performance des produits de croissance Cosentyx (USD 1,1 milliard) a…
-
Press release /Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…
-
Press release /V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%…
-
Clinical Trials /
-
Press release /Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
-
Press release /Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)…